title: HIV envelope: challenges and opportunities for development of entry inhibitors.
abstract: The HIV envelope proteins glycoprotein 120 (gp120) and glycoprotein 41 (gp41) play crucial roles in HIV entry, therefore they are of extreme interest in the development of novel therapeutics. Studies using diverse methods, including structural biology and mutagenesis, have resulted in a detailed model for envelope-mediated entry, which consists of multiple conformations, each a potential target for therapeutic intervention. In this review, the challenges, strategies and progress to date for developing novel entry inhibitors directed at disrupting HIV gp120 and gp41 function are discussed.
authors.affiliation: Department of Biochemistry and Molecular Genetics, University of Illinois, Chicago, IL 60607, USA. caffrey@uic.edu
authors.forename: Michael
authors.initials: M
authors.lastname: Caffrey
mesh_terms: D006678:HIV / Q000737:chemistry* / Q000187:drug effects* / Q000502:physiology; D023581:HIV Fusion Inhibitors / Q000378:metabolism* / Q000494:pharmacology*; D006801:Humans; D011487:Protein Conformation; D053586:Virus Internalization; D054299:env Gene Products, Human Immunodeficiency Virus / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000378:metabolism*
chemical_list: D023581:HIV Fusion Inhibitors; D054299:env Gene Products, Human Immunodeficiency Virus